Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864174 · ClinicalTrials.gov registry record · Phase 4
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,736
- Enrollment target
NCT01864174 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,736 participants.
The verdict
NCT01864174, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,736 participants
- Enrollment target
Study Summary
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
Interventions
- DRUG Metformin XR
- DRUG Metformin IR
- DRUG Placebo matching with Metformin XR
- DRUG Placebo matching with Metformin IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,736 participants |
| Start Date | 2013-06-20 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864174
The ClinicalTrials.gov registry entry for NCT01864174 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,736 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin XR is the first listed.
NCT01864174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01864174 about?
NCT01864174 is a clinical study titled "Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes". The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
What is the current status of trial NCT01864174?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,736 participants. The study started on 2013-06-20. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT01864174?
The interventions under investigation include: Metformin XR (DRUG), Metformin IR (DRUG), Placebo matching with Metformin XR (DRUG), Placebo matching with Metformin IR (DRUG).
Who is sponsoring clinical trial NCT01864174?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.